

Press release 2023-08-31

AcuCort signs partnership agreement for the four major Nordic countries with Unimedica Pharma

AcuCort AB has today signed a partnership agreement for Sweden, Norway, Denmark and Finland with Unimedica Pharma. The agreement means that Unimedica will be responsible for sales and marketing of AcuCort's oral film Zeqmeli[®] in these countries.

With the agreement, AcuCort enters the commercialization phase that the company has been preparing for a long time. Previously, the company's oral film Zeqmeli[®] has received approval from pharmaceutical authorities in Sweden, Denmark, Norway and Finland, which allows for a commercial venture in these countries.

"The agreement with Unimedica Pharma is important for our success in the Nordic markets. Unimedica Pharma is a very reputable company with specialist expertise in the sales and marketing of pharmaceuticals in the Nordics, which we now benefit from as AcuCort enters a new chapter on its growth journey", says AcuCort's CEO Jonas Jönmark.

Unimedica Pharma's CEO Johan Frödin says in a comment:

"We have followed AcuCort for a long time and have been impressed by the innovative power that exists in the company. Zeqmeli is a product that fits well into our range and contributes to our vision of enabling a better life. We look forward to the collaboration with AcuCort and have great expectations for the launch of Zeqmeli on the Nordic markets."

For further information please contact:

Jonas Jönmark, CEO, AcuCort AB

Phone: 070 365 5400

E-mail: jonas.jonmark@acucort.se

This disclosure contains information that AcuCort is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 31-08-2023 at 17:35 CET.

About Unimedica Pharma

Unimedica Pharma is a Swedish specialist pharmaceutical company that today supplies the Nordics and Northern Europe with a wide range of medicines in several therapeutic areas. The business is divided into three main business areas: Registered specialist medicines, Licensed medicines, Contract manufacturing (CDMO). The company's head office is in Solna and the company is a wholly owned subsidiary of MedCap AB (publ), which is listed on Nasdaq Stockholm Mid Cap. Read more at: www.unimedica.se.

About AcuCort AB (publ)

AcuCort has developed and commercializes Zeqmeli[®], a new fast-dissolving oral film to be placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy and for the treatment of patients with covid-19 who need supplemental oxygen therapy. Zeqmeli[®] is approved in Sweden, Denmark, Norway and Finland. AcuCort (short name: ACUC) is listed on the Spotlight Stock Market. Please visit www.acucort.se.